CHX reports positive results from final pivotal trial of Prevora antibacterial tooth coating for cavity prevention

CHX Technologies Inc., a private Canadian pharmaceutical company that is developing new treatments for the prevention of dental diseases, today announced successful results in its final controlled pivotal trial of Prevora, its proprietary antibacterial tooth coating for the prevention of cavities. The trial surpassed objectives set by the Food and Drug Administration (FDA) protocol, clearing the way for CHX to start the process of seeking FDA approval for use in the United States.  In this study Prevora was shown to reduce cavities by 37% (p = 0.04) over one year in all participants, and most profoundly, by 60%.

Prevora is a proprietary topical coating developed by CHX which is applied to the teeth of the patient by the hygienist in a short, painless appointment. The active ingredient, chlorhexidine, is a well-known antiseptic used in both dentistry and medicine.  Prevora works by attacking the bacteria Streptococci mutans, which cause tooth decay.  

Tooth decay is the most common infection in adults, ranks as one of the most expensive diseases and is implicated as a significant contributor to overall health. The U.S. Center for Disease Control reports that 23% of American adults have untreated tooth decay.  

The Phase IIIB study of Prevora found that the worst tooth decay was amongst the uninsured and public health groups, which account for half of Americans today.  The number of uninsured Americans is growing quickly as baby boomers retire, as large employers change their benefit plans, and as working in small business or being self-employed becomes more common.  

"In this context, Prevora's profound prevention of tooth decay, especially for the uninsured, is timely and creates a new, painless and effective preventive service for the dental office to offer a changing market." said Ross Perry, President of CHX.